Merus NV
MRUS68.220USD
-0.730-1.06%
終値 09/19, 16:00（ET）15分遅れの株価
5.16B時価総額
損失額直近12ヶ月PER
詳細情報 Merus NV 企業名
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
企業情報
企業コードMRUS
会社名Merus NV
上場日May 19, 2016
最高経営責任者「CEO」Dr. Sven Ante (Bill) Lundberg, M.D.
従業員数260
証券種類Ordinary Share
決算期末May 19
本社所在地Yalelaan 62
都市UTRECHT
証券取引所NASDAQ Global Market Consolidated
国Netherlands
郵便番号3584 CM
電話番号310302538800
ウェブサイトhttps://merus.nl/
企業コードMRUS
上場日May 19, 2016
最高経営責任者「CEO」Dr. Sven Ante (Bill) Lundberg, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, Aug 15
更新時刻: Fri, Aug 15
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
8.22%
Paradigm BioCapital Advisors LP
5.66%
RTW Investments L.P.
5.29%
Wellington Management Company, LLP
4.93%
Commodore Capital LP
4.66%
他の
71.24%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
8.22%
Paradigm BioCapital Advisors LP
5.66%
RTW Investments L.P.
5.29%
Wellington Management Company, LLP
4.93%
Commodore Capital LP
4.66%
他の
71.24%
種類
株主統計
比率
Investment Advisor/Hedge Fund
37.28%
Hedge Fund
34.60%
Investment Advisor
26.56%
Corporation
1.93%
Venture Capital
1.78%
Research Firm
1.13%
Private Equity
0.94%
Individual Investor
0.37%
Pension Fund
0.35%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.10M
1.47%
-21.08K
-1.89%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.50M
2.02%
+508.06K
+51.16%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
